Want to see RXRX full AI Analyst Report?
RXRX Stock Chart & Stats
$2.96
-$0.05(-1.66%)
At close: 4:00 PM EDT
$2.96
-$0.05(-1.66%)
Day’s Range― - ―
52-Week Range$2.77 - $7.18
Previous CloseN/A
Volume16.53M
Average Volume (3M)21.80M
Market Cap
$1.88B
Enterprise Value$1.47K
Total Cash (Recent Filing)$545.68M
Total Debt (Recent Filing)$61.88M
Price to Earnings (P/E)―
Beta3.20
Next Earnings
Nov 11, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding535,342,160
10 Day Avg. Volume21,518,381
30 Day Avg. Volume21,799,392
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.43Price Target Upside117.34% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$50.47M
Bulls Say, Bears Say
Bulls Say
AI-enabled Discovery EfficiencyRecursion’s integrated AI, automation, and biological testing platform may reduce discovery time and experimental requirements. If repeatable, this efficiency can improve capital productivity and strengthen its value to partners over multiple programs.
Validated Partnership PlatformSubstantial partner payments provide external validation of Recursion’s platform and diversify funding beyond equity markets. Ongoing programs and potential milestones or royalties could support future cash generation while internal candidates mature.
Advancing Clinical PipelineA broader clinical pipeline creates several opportunities for proof-of-concept, partnerships, and eventual product revenue. REC-4881’s early efficacy signal and REC-7735’s cleared IND provide tangible development progress beyond platform claims.
Bears Say
Persistent Cash Burn And LossesThe company remains substantially dependent on external funding and partnership receipts because operations are not self-financing. Continued losses can erode equity and may force financing, asset transactions, or reduced investment before products generate revenue.
Weak And Volatile Revenue BaseDeclining revenue and negative gross profit indicate that collaboration income has not yet produced a stable operating model. This limits visibility into recurring revenue, constrains operating leverage, and leaves results sensitive to milestone timing.
Clinical, Regulatory, And Funding Timing RiskMost pipeline value still depends on uncertain clinical outcomes, regulatory alignment, and timely execution. If readouts or approvals are delayed beyond the stated early-2028 runway, Recursion could need additional capital before major commercial milestones arrive.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals, Inc’s price range in the past 12 months?
Recursion Pharmaceuticals, Inc lowest stock price was $2.77 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals, Inc’s market cap?
Recursion Pharmaceuticals, Inc’s market cap is $1.88B.
When is Recursion Pharmaceuticals, Inc’s upcoming earnings report date?
Recursion Pharmaceuticals, Inc’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Recursion Pharmaceuticals, Inc’s earnings last quarter?
Recursion Pharmaceuticals, Inc released its earnings results on Aug 05, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.01.
Is Recursion Pharmaceuticals, Inc overvalued?
According to Wall Street analysts Recursion Pharmaceuticals, Inc’s price is currently Undervalued.
Does Recursion Pharmaceuticals, Inc pay dividends?
Recursion Pharmaceuticals, Inc does not currently pay dividends.
What is Recursion Pharmaceuticals, Inc’s EPS estimate?
Recursion Pharmaceuticals, Inc’s EPS estimate is -0.22.
How many shares outstanding does Recursion Pharmaceuticals, Inc have?
Recursion Pharmaceuticals, Inc has 535,342,160 shares outstanding.
What happened to Recursion Pharmaceuticals, Inc’s price movement after its last earnings report?
Recursion Pharmaceuticals, Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -4.23%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals, Inc?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.43 (117.34% Upside)
$6.43 (117.34% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.89%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals, Inc
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strong set of operational and technical highlights: multiple advancing clinical programs with compelling early efficacy (REC-4881), a cleared IND for a precision-selective oncology candidate (REC-7735), large proprietary data assets (>50 PB, massive cellular atlases), meaningful partnership cash inflows (> $500M realized, > $260M from Roche-Genentech) and demonstrated efficiency gains in design speed and operating costs (guidance lowered to $375M, ~40% reduction vs 2024 pro forma). Key risks and lowlights are typical for a clinical-stage biotech: regulatory and clinical uncertainty in rare disease and CNS programs, timing of pivotal data (some milestones extend beyond the current cash runway), competitive pressure as AI tools proliferate, and the early-stage nature of some proofs. Overall, positive operational momentum and external validation from partners outweigh the remaining clinical and market risks, but the company still faces execution and timing risks as programs advance.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$6.43
▲(117.34% Upside)
Technical Analysis
Ownership Overview
2.89% Insiders
12.72% Mutual Funds
22.96% Other Institutional Investors
33.95% Public Companies and Individual Investors